Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma

Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Clin Oncol
Autors principals: Kamachi, Naoki, Shimose, Shigeo, Hirota, Keisuke, Koya, Shunji, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Hashida, Ryuki, Kawaguchi, Takumi, Matuse, Hiroo, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2021
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7947949/
https://ncbi.nlm.nih.gov/pubmed/33758660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2241
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars